CBMX is focused on children-focused diagnostic tests, with the NIH saying their technology is becoming the standard of care. CLRX is working with LIFE on providing information on how to best evaluate diagnostic cancer test results. There is some synergy there in terms of trading, in terms of revenue being tied to diagnostic testing, although CLRX's revenue here won't ramp until 2014 when LIFE rolls out its molecular tests with CLRX knowledge-based, decision support information.
Its more the seeking alpha author who wrote a great article on CLRX and likes it a lot- he wrore an article on CBMX saying it would double and it did. The same author believes CLRX is cheap. If the author writes another positive story on CLRX because of his track record the stock could double in the day-